Dawit Assefa Arimide1,2, Minilik Demissie Amogne2,3, Yenew Kebede4, Taye T Balcha1, Fekadu Adugna5, Artur Ramos6, Joshua DeVos6, Clement Zeh6, Anette Agardh3, Joy Chih-Wei Chang6, Per Björkman1, Patrik Medstrand1. 1. Department of Translational Medicine, Lund University, Malmo, Sweden. 2. TB/HIV Department, Ethiopian Public Health Institute, Addis Ababa, Ethiopia. 3. Department of Clinical Sciences, Lund University, Malmo, Sweden. 4. Africa Centre for Disease Prevention and Control, Africa Union Commission, Addis Ababa, Ethiopia. 5. NPO - HIV/AIDS, World Health Organization, Addis Ababa, Ethiopia. 6. Division of Global HIV & TB, Center for Global Health, Center for Disease Control and Prevention, Atlanta, GA.
Abstract
OBJECTIVE: To determine viral load (VL) nonsuppression (VLN) rates, HIV drug resistance (HIVDR) prevalence, and associated factors among female sex workers (FSWs) in Ethiopia. METHODS: A cross-sectional biobehavioral survey was conducted among FSWs in 11 cities in Ethiopia in 2014. Whole blood was collected, and HIVDR genotyping was performed. Logistic regression analysis was performed to identify factors associated with VLN and HIVDR. RESULTS: Among 4900 participants, 1172 (23.9%) were HIV-positive and 1154 (98.5%) had a VL result. Participants were categorized into antiretroviral therapy (ART) (n = 239) and ART-naive (n = 915) groups based on self-report. From the 521 specimens (ART, 59; ART-naive, 462) with VL ≥1000 copies/mL, genotyping was successful for 420 (80.6%) and 92 (21.9%) had drug resistance mutations (DRMs). Pretreatment drug resistance (PDR) was detected in 16.5% (63/381) of the ART-naive participants. Nucleoside reverse transcriptase inhibitor (NRTI), non-NRTIs (NNRTIs), and dual-class DRMs were detected in 40 (10.5%), 55 (14.4%), and 35 (9.2%) of the participants, respectively. Among 239 participants on ART, 59 (24.7%) had VLN. Genotyping was successfully performed for 39 (66.1%). DRMs were detected in 29 (74.4%). All 29 had NNRTI, 23 (79.3%) had NRTI or dual-class DRMs. VLN was associated with age 35 years or older, CD4+ T-cell count <350 cells/mm3, and being forced into selling sex. PDR and acquired drug resistance were associated with CD4+ T-cell count <350 cells/mm3 (P < 0.001). CONCLUSIONS: The high VLN and HIVDR rates among FSWs underscore the need for targeted interventions to improve ART access and virologic monitoring to maximize the benefit of ART and limit the spread of HIV and HIVDR.
OBJECTIVE: To determine viral load (VL) nonsuppression (VLN) rates, HIV drug resistance (HIVDR) prevalence, and associated factors among female sex workers (FSWs) in Ethiopia. METHODS: A cross-sectional biobehavioral survey was conducted among FSWs in 11 cities in Ethiopia in 2014. Whole blood was collected, and HIVDR genotyping was performed. Logistic regression analysis was performed to identify factors associated with VLN and HIVDR. RESULTS: Among 4900 participants, 1172 (23.9%) were HIV-positive and 1154 (98.5%) had a VL result. Participants were categorized into antiretroviral therapy (ART) (n = 239) and ART-naive (n = 915) groups based on self-report. From the 521 specimens (ART, 59; ART-naive, 462) with VL ≥1000 copies/mL, genotyping was successful for 420 (80.6%) and 92 (21.9%) had drug resistance mutations (DRMs). Pretreatment drug resistance (PDR) was detected in 16.5% (63/381) of the ART-naive participants. Nucleoside reverse transcriptase inhibitor (NRTI), non-NRTIs (NNRTIs), and dual-class DRMs were detected in 40 (10.5%), 55 (14.4%), and 35 (9.2%) of the participants, respectively. Among 239 participants on ART, 59 (24.7%) had VLN. Genotyping was successfully performed for 39 (66.1%). DRMs were detected in 29 (74.4%). All 29 had NNRTI, 23 (79.3%) had NRTI or dual-class DRMs. VLN was associated with age 35 years or older, CD4+ T-cell count <350 cells/mm3, and being forced into selling sex. PDR and acquired drug resistance were associated with CD4+ T-cell count <350 cells/mm3 (P < 0.001). CONCLUSIONS: The high VLN and HIVDR rates among FSWs underscore the need for targeted interventions to improve ART access and virologic monitoring to maximize the benefit of ART and limit the spread of HIV and HIVDR.
Authors: Roos E Barth; Maarten F Schim van der Loeff; Rob Schuurman; Andy I M Hoepelman; Annemarie M J Wensing Journal: Lancet Infect Dis Date: 2010-03 Impact factor: 25.071
Authors: M Aklilu; T Messele; A Tsegaye; T Biru; D H Mariam; B van Benthem; R Coutinho; T Rinke de Wit; A Fontanet Journal: AIDS Date: 2001-01-05 Impact factor: 4.177
Authors: Wim Delva; Jeffrey W Eaton; Fei Meng; Christophe Fraser; Richard G White; Peter Vickerman; Marie-Claude Boily; Timothy B Hallett Journal: PLoS Med Date: 2012-07-10 Impact factor: 11.069
Authors: Ravindra K Gupta; Michael R Jordan; Binta J Sultan; Andrew Hill; Daniel H J Davis; John Gregson; Anthony W Sawyer; Raph L Hamers; Nicaise Ndembi; Deenan Pillay; Silvia Bertagnolio Journal: Lancet Date: 2012-07-23 Impact factor: 79.321
Authors: Soo-Yon Rhee; Jose Luis Blanco; Michael R Jordan; Jonathan Taylor; Philippe Lemey; Vici Varghese; Raph L Hamers; Silvia Bertagnolio; Tobias F Rinke de Wit; Avelin F Aghokeng; Jan Albert; Radko Avi; Santiago Avila-Rios; Pascal O Bessong; James I Brooks; Charles A B Boucher; Zabrina L Brumme; Michael P Busch; Hermann Bussmann; Marie-Laure Chaix; Bum Sik Chin; Toni T D'Aquin; Cillian F De Gascun; Anne Derache; Diane Descamps; Alaka K Deshpande; Cyrille F Djoko; Susan H Eshleman; Herve Fleury; Pierre Frange; Seiichiro Fujisaki; P Richard Harrigan; Junko Hattori; Africa Holguin; Gillian M Hunt; Hiroshi Ichimura; Pontiano Kaleebu; David Katzenstein; Sasisopin Kiertiburanakul; Jerome H Kim; Sung Soon Kim; Yanpeng Li; Irja Lutsar; Lynn Morris; Nicaise Ndembi; Kee Peng Ng; Ramesh S Paranjape; Martine Peeters; Mario Poljak; Matt A Price; Manon L Ragonnet-Cronin; Gustavo Reyes-Terán; Morgane Rolland; Sunee Sirivichayakul; Davey M Smith; Marcelo A Soares; Vincent V Soriano; Deogratius Ssemwanga; Maja Stanojevic; Mariane A Stefani; Wataru Sugiura; Somnuek Sungkanuparph; Amilcar Tanuri; Kok Keng Tee; Hong-Ha M Truong; David A M C van de Vijver; Nicole Vidal; Chunfu Yang; Rongge Yang; Gonzalo Yebra; John P A Ioannidis; Anne-Mieke Vandamme; Robert W Shafer Journal: PLoS Med Date: 2015-04-07 Impact factor: 11.069
Authors: Benjamin Chimukangara; Richard J Lessells; Soo-Yon Rhee; Jennifer Giandhari; Ayesha B M Kharsany; Kogieleum Naidoo; Lara Lewis; Cherie Cawood; David Khanyile; Kassahun A Ayalew; Karidia Diallo; Reshmi Samuel; Gillian Hunt; Alain Vandormael; Babill Stray-Pedersen; Michelle Gordon; Tariro Makadzange; Photini Kiepiela; Gita Ramjee; Johanna Ledwaba; Monalisa Kalimashe; Lynn Morris; Urvi M Parikh; John W Mellors; Robert W Shafer; David Katzenstein; Pravi Moodley; Ravindra K Gupta; Deenan Pillay; Salim S Abdool Karim; Tulio de Oliveira Journal: EClinicalMedicine Date: 2019-03-18
Authors: Kathryn Elizabeth Lancaster; Kimberly A Powers; Thandie Lungu; Pearson Mmodzi; Mina C Hosseinipour; Katy Chadwick; Vivian F Go; Brian W Pence; Irving F Hoffman; William C Miller Journal: PLoS One Date: 2016-01-25 Impact factor: 3.240